Exploring & exploiting our 'other self' - Does the microbiota hold the key to the future therapy in Crohn's?
Exploring & exploiting our 'other self' - Does the microbiota hold the key to the future therapy in Crohn's?
复制标题
DOI：
10.1016/j.bpg.2014.04.001
复制
发表时间：
2014-06-01
影响因子：
3.2
通讯作者：
Siegmund, Britta
中科院分区：
文献类型：
--
作者：
Haag, Lea-Maxie;Siegmund, Britta
炎症性肠病（IBD）以其两种主要形式克罗恩病（CD）和溃疡性结肠炎（UC）是导致胃肠道炎症的慢性复发性疾病。虽然IBD的确切病因尚不清楚，但据信有几个因素有助于疾病的发病机制。其中，肠道微生物群的作用越来越受到重视。来自实验和临床研究的证据强烈表明，慢性肠道炎症是由遗传易感宿主对微生物群组分的免疫应答失调引起的。微生物群作为疾病发病机制的主要驱动因素的认识日益增长，这提出了一个问题，即肠道微生物群是否可以用作CD的治疗靶点。根据我们对宿主微生物群在健康和疾病中相互作用的了解，本文的目的是解决微生物群是否是CD未来治疗的关键的问题。(C)2014爱思唯尔有限公司版权所有。
Inflammatory bowel diseases (IBD) with its two major forms Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders leading to inflammation of the gastrointestinal tract. Although the precise aetiology of IBD remains unclear, several factors are believed to contribute to disease pathogenesis. Among these, the role of the intestinal microbiota has become more and more appreciated. Evidence from experimental and clinical studies strongly suggests that chronic intestinal inflammation results from a dysregulated immune response towards components of the microbiota in genetically susceptible hosts. The growing perception of the microbiota as a major driver of disease pathogenesis raises the question, if the intestinal microbiota can be used as a therapeutic target in CD. Based on what we know about host microbiota interactions in health and disease, the objective of this review is to address the question if the microbiota holds the key to the future therapy in CD. (C) 2014 Elsevier Ltd. All rights reserved.